Menu
Recruiting NCT07255261

Evaluation of Facial HA Dermal Fillers in Real-Life Conditions

No phase Interventional Lips Enhancement Perioral Wrinkles Nasolabial Fold Wrinkles Cheek Augmentation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Facial injection of hyaluronic acid-based dermal fillers..
Who it may be relevant to
Registry conditions: Lips Enhancement, Perioral Wrinkles, Nasolabial Fold Wrinkles, Cheek Augmentation. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Post-Marketing Clinical Follow Up On Hyaluronic Acid-Based Dermal Fillers Using COLD-X™ Technology By Symatese

Overview

The goal of this post-market interventional study is to confirm, under real-life conditions, the safety and performance of hyaluronic acid-based dermal fillers intended to modify skin anatomy and facial appearance. Subjects aged 18 years or older seeking aesthetic treatment of the lips, perioral lines, nasolabial folds, cheeks, and/or infraorbital hollows may be included. The main question the study aims to answer is: How long does the effect of the products last? Participants will attend follow-up visits every 6 months after the initial injection, until the end of follow-up at 24 months. During each visit, the investigator will assess performance and safety through a simple clinical examination. At each follow-up visit, subjects will also evaluate the aesthetic improvement compared with their pre-injection appearance. Subjects will be asked about the level of pain experienced during the initial injection. If the subject wishes, a retreatment may be performed at the 12-month or 18-month follow-up visit, provided that the treated area(s) have returned to the pre-injection state.

Interventions

  • Device Facial injection of hyaluronic acid-based dermal fillers.
    Facial injection of hyaluronic acid-based dermal fillers USING COLD-X™ TECHNOLOGY by Symatese.

Primary outcome measures

  • Number of patients returning to their baseline (pre-injection) state for each treated area, based on the investigator's assessment using 5- or 6-point area-specific scales. [Time frame: At each follow-up visit (6 months, 12 months, 18 months and 24 months)]
Secondary outcome measures (6)
  • Injection site reactions (ISR) assessed by the investigators. [Time frame: D0 (post-first injection), M1 (post optional touch-up), M12/M18 (post optional retreatment)]
  • Number of adverse device effects (ADEs) and serious adverse device effects (SADEs) assessed by the investigators. [Time frame: From the injection (day 0) to the end of the follow-up period (24 months).]
  • Subject-assessed aesthetic improvement of each treated area, measured using the Global Aesthetic Improvement Scale (GAIS), a 5-point scale ranging from "worse" to "very much improved. [Time frame: At each visit (Day 0 after injection, day 30 (if any visit), 6 months, 12 months, 18 months and 24 months)]
  • Investigator-assessed aesthetic improvement of each treated area, measured using the Global Aesthetic Improvement Scale (GAIS), a 5-point scale ranging from "worse" to "very much improved. [Time frame: At each visit (Day 0 after injection, day 30 (if any visit), 6 months, 12 months, 18 months and 24 months)]
  • Investigator-assessed wrinkle severity or volume using 5- or 6-point area-specific scales for each treated area. [Time frame: At each visit (Day 0 before and after injection, at 30 Days (if any visit), 6 months, 12 months, 18 months, and 24 months)]
  • Subject-reported pain per treated area, rated on an 11-point scale (0 = no pain, 10 = worst pain). [Time frame: During the initial injection procedure at day 0]

Eligibility criteria

Inclusion criteria

  • Subject seeking an aesthetic correction of the infraorbital hollows with FASY P and/ or an aesthetic correction of the lips with ESTYME® LIPS, and/ or an aesthetic correction of the perioral lines with ESTYME® SMOOTH, and/ or an aesthetic correction of nasolabial folds with ESTYME® SMOOTH, and/ or an aesthetic correction of cheeks with ESTYME® SCULPT.
  • Subject who agreed to participate and have signed an informed consent.
  • Age: over 18 years old.
  • Subject being affiliated to a health social security system.

Exclusion criteria

  • Minors
  • Subjects with a known allergy to hyaluronic acid, lidocaine or amide local anesthetics.
  • Subjects with porphyria.
  • Subjects with an autoimmune disorder, or using an immunosuppressant medication.
  • Pregnant or breastfeeding women.
  • Subjects with inflammation, infection or cutaneous disorders, at the treatment site or nearby.
  • Subjects with bleeding disorders or in subjects receiving thrombolytic or anticoagulant treatment.
  • Areas other than those recommended by the IFU.
  • Subject deprived of liberty by judicial or administrative decision.
  • Adults under a legal protection measure (guardianship/curatorship).
  • Subject under legal protection order.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

France · 8 centers
  • Centre Médical Saint Jean — Arras
  • Cabinet médical — Lyon
  • Palais de Flore — Lyon
  • Centre Laser Palaiseau — Palaiseau
  • Aesthé - Marais. — Paris
  • Cabinet médical — Paris
  • Cabinet médical — Paris
  • Cabinet médical — Saint-Maur-des-Fossés

Identifiers

NCT: NCT07255261 · CLIN2108_CIP

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗